Alerta

ANTIVIRAL SULFATED CHITOSAN DERIVATIVES

Resumen de: US2025152618A1

The invention relates to sulfated chitosan derivatives of formula (I), wherein the meanings for the various substituents are as disclosed in the description, for their use in the treatment and/or prevention of a viral infection, particularly wherein the viral infection is caused by SARS-CoV-2 such as COVID-19 or RSV.

NEUTRALIZING ANTIBODIES AGAINST SARS-RELATED CORONAVIRUS

Resumen de: US2025154230A1

The present invention relates to antibodies or antigen-binding fragments thereof against SARS-related coronavirus, pharmaceutical compositions comprising such antibodies or antigen-binding fragments thereof, a kit comprising such antibodies or antigen-binding fragments thereof, and the antibodies or antigen-binding fragments thereof and the pharmaceutical composition and the kit for use as a medicament, and in the treatment or prevention of a disease caused by SARS-related coronavirus.

LYOPHILIZED MRNA-LNP VACCINE PRODUCTS

Resumen de: WO2025098237A1

A lyophilized RNA-LNP (e.g., mRNA-lipid nanoparticle), a method of making or using the same, such as for vaccination using an mRNA encoding an antigenic vaccine (e.g., SARS-CoV-2).

MODIFIED PRIMARY IMMUNE CELLS FOR INDUCTION OR ENHANCEMENT OF IMMUNOTHERAPY

Resumen de: US2025152710A1

Provided herein are compositions with an augmented capacity to mediate ADCC. These compositions include chimeric NK cells—called “Nukes” (NK Enhancement Strategy) that express CD64 Fc receptor from an exogenous nucleic acid molecule, the NK cells having antibodies bound thereto. Methods of using these cells for treatment of HIV, cancer, SARS-COV-2, and other diseases are provided.

USE OF AMINOPYRIDINE, IN PARTICULAR AMIFAMPRIDINE, FOR THE TREATMENT OF A VIRALLY-ASSOCIATED FATIGUE

Resumen de: US2025152566A1

The present invention relates to a new use of an Aminopyridine, such as Pyridine-3,4-diamine, a derivative thereof and/or of a physiologically tolerable salt thereof for the prevention and/or treatment of a fatigue, which is associated with a viral infection, preferably by SARS-CoV-2. In particular for the treatment of fatigue in connection with a “post-COVID phase” and the “long COVID-19 syndrome”.

NUCLEOSIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST CORONAVIRUSES

Resumen de: EP4553080A1

The invention relates to small molecule inhibitors of formula (I) targeting the nspl4 protein of SARS-CoV-2 and other coronaviruses, for use as antiviral agents directly targeting viral proteins.

USE OF IFN-LAMBDA MRNA FOR TREATING VIRAL INFECTIONS

Resumen de: EP4553084A2

The present invention relates to pharmaceutical compositions comprising an mRNA encoding an IFN-λ polypeptide for use in treating a viral-induced disorder, preferably a viral-induced respiratory disorder, such as COVID-19.

SARS-CoV-2 ACE2 Transgenic mouse expressing humanized ACE2 susceptible for SARS-CoV-2 virus infection and production method therefor

Resumen de: WO2025100882A1

The present invention discloses: a humanized ACE2-expressing transgenic mouse susceptible to SARS-CoV-2 virus infection, the mouse being obtained by applying a CRISPR system; and a method for producing same. The humanized ACE2-expressing transgenic mouse according to the present invention reflects the severity of symptoms, mortality patterns, and the like according to age, sex, viral infection dose, and the like, as observed in human COVID-19 cases, and reproduces immunopathological characteristics of SARS-CoV-2 infection in the lungs without viral replication or lesions in the brain, and thus can be effectively used to understand the pathogenesis of SARS-CoV-2 and to develop vaccines or therapeutic agents.

2 A Immunoglobulin A antibody for neutralizing SARS coronavirus 2 spike antigen and uses thereof

Resumen de: KR20250064724A

본 발명은 사스 코로나바이러스 2 스파이크 항원에 특이적으로 결합하는 이뮤노글로불린 A 항체를 제조하여 이를 사스 코로나바이러스 2 검출 또는 진단 용도로 사용하거나 사스 코로나바이러스 2 중화 효과를 기반으로 사스 코로나바이러스 2 감염질환 예방 또는 치료하기 위해 사용하는 용도에 관한 것이다.

2 A Immunoglobulin A antibody for neutralizing SARS coronavirus 2 spike antigen and uses thereof

Resumen de: KR20250064725A

본 발명은 사스 코로나바이러스 2 스파이크 항원에 특이적으로 결합하는 이뮤노글로불린 A 항체를 제조하여 이를 사스 코로나바이러스 2 검출 또는 진단 용도로 사용하거나 사스 코로나바이러스 2 중화 효과를 기반으로 사스 코로나바이러스 2 감염질환 예방 또는 치료하기 위해 사용하는 용도에 관한 것이다.

BETA-CORONAVIRUS FUSION RECOMBINANT PROTEIN, AND PREPARATION METHOD AND APPLICATION THEREOF

Resumen de: US2025144062A1

Disclosed is a betacoronavirus fusion recombinant protein, comprising an RBD region and a COVID19-SF5 fragment of a spike protein of SARS-COV-2 (COVID-19), and an amino acid sequence of the COVID19-SF5 fragment is an 880th amino acid to a 1084th amino acid of the S protein of the novel coronavirus COVID-19. According to the invention, a constant conserved fragment (COVID19-SF5) and a receptor binding domain (RBD) fragment are fused and expressed to provide a more-effective constant universal vaccine candidate recombinant fusion protein for such type of coronavirus, thus providing broader and better protection measures from two standpoints of inhibiting receptor recognition and providing universal protection.

PEPTIDE

Resumen de: US2025145667A1

The present invention relates to peptides derived from COVID-19 virus envelope protein and spike protein. The invention further relates to polynucleotides and vectors encoding said peptides, and antibodies and chimeric antigen receptors that bind to said peptides. The invention also relates to methods of diagnosis and prediction of conditions in a subject which leverage recognition of said peptides, such as by antigen-specific T cells.

TETANUS VACCINE PLATFORM FOR EMBEDDING COVID-19 VACCINE

Resumen de: US2025144201A1

A method of immunizing against COVID-19 by administering a recombinant SARS-CoV2 protein-based vaccine, developed by either embedding the epitopes/domains, or chemically attaching, to an already established vaccine candidate, e.g., a detoxified recombinant tetanus neurotoxin (DrTeNT). The developed vaccine will have three novel contributions compared to the present vaccine technology: a) providing a novel and very effective vaccine platform; b) priming with DrTeNT will prepare the host immune system for better response; and c) oral delivery of the vaccine candidate with a group of neurotoxin binding proteins (NAPs) from Clostridium sp. A Detoxified recombinant tetanus neurotoxin (DrTeNT) is prepared by mutation of the active site amino acid residues is an effective vaccine candidate, and is used for embedding epitopes of SARS-CoV-2 virus protein for vaccination against Covid-19. DrTeNT is a risk-free vaccine, free of formalin or any other chemical adjuvants.

COMPOSITIONS AND METHODS FOR TREATING BIOFILMS AND NEUTROPHIL EXTRACELLULAR TRAP FORMATION

Resumen de: AU2023375471A1

Provided herein is a synthetic polypeptide derived from High Mobility Group Box 1 (HMGB 1) host protein that can both disrupt bacterial biofilms and prevent Neutrophil Extracellular Trap (NET) formation. Also provided herein are methods to disrupt aberrant or excessive NET formation that are particularly well-suited to treat high-risk populations such as those infected with SARS CoV-2, sepsis, autoimmune diseases e.g., systemic lupus erythematosus, rheumatoid arthritis, Type I diabetes mellitus, small vessel vasculitis, autoinflammatory diseases e.g., gout, inflammatory bowel disease, and metabolic diseases e.g., Type 2 diabetes and obesity.

COMPOSITIONS AND METHODS FOR FcRn-TARGETED INTRANASAL CORONAVIRUS VACCINATION

Resumen de: US2025144199A1

The present disclosure relates generally to novel recombinant coronavirus-based fusion proteins (“RBDs-IgG Fc protein” and “RBDs protein”) and vaccine compositions using the same, in which the fusion proteins comprise tandemly arranged coronaviruses receptor binding domains (RBDs). The present disclosure further provides methods and kits for immunizing a subject using the compositions.

SARS-CoV-2 USE OF NOVEL POLYMER FOR PREVENTING SARS-COV-2

Resumen de: US2025134989A1

The present invention relates to a novel vaccine composition for coronavirus infection-19 comprising a polymer-based mRNA carrier. Specifically, the present invention provides a vaccine composition comprising an mRNA carrier using a novel polymer capable of delivering a negatively charged genetic material such as mRNA, and the vaccine composition has excellent effects of enhanced in vivo immune activity such as high antibody formation ability and increased interferon-gamma production.

THERAPEUTIC TREATMENT FOR THE CORONAVIRUS DISEASE COVID-19

Resumen de: US2025144163A1

A therapeutic treatment for the treatment of COVID-19 disease, the treatment to be initiated soon after and preferably within approximately twenty four hours after a patient develops the first signs of symptoms comprising but not limited to individually or in combination thereof fever, headache, sore joints, cough, fatigue, chills. The treatment consists of the oral administration of an extracted component or a combination of extracted components of an herb thyme leaf also know as common thyme (Thymus Vulgaris). The treatment is thought to inhibit the replication and activity of the virus allowing the patient to regain normal health and assist in developing immunity to the virus. The treatment is not known to completely eliminate the virus from the patient therefore resulting in the patient possibly developing the same or different symptoms of the disease a second, or more times requiring additional treatments of the disclosed thyme therapeutic treatment.

HUMAN MONOCLONAL ANTIBODIES TARGETING THE S2 SUBUNIT OF THE SARS-COV-2 SPIKE PROTEIN

Resumen de: US2025145691A1

Provided herein are antibodies and antibody fragments that bind to the S2 subunit of the SARS-CoV-2 spike protein. Methods of treating or preventing SARS-CoV-2 infections are provided, comprising administering to a patient in need thereof an effective amount of a SARS-CoV-2 spike protein S2 subunit-targeting antibody.

CHIMERA MOLECULES FOR SARS-COV-2 AND METHODS OF USE

Resumen de: US2025145692A1

The subject matter described herein is directed to a chimera molecule such as a polypeptide or protein chimera useful for treating or preventing a viral infection or reducing the severity, incidence, or transmissibility of a viral infection, to nucleic acid molecules encoding the polypeptide or protein chimera, and to pharmaceutical compositions containing them. Also, methods of generating such antiviral polypeptide or protein chimera, of generating nucleic acid molecules encoding the antiviral polypeptide or protein chimera, and of generating pharmaceutical compositions containing the same, and methods of using the same for treatment or prevention of a SARS-CoV-2 infection, or to reduce the severity, incidence, or transmissibility of a of a SARS-CoV-2 infection, are described.

METHODS AND DEVICES FOR RAPID DETECTION OF COVID-19 AND OTHER PATHOGENS

Resumen de: US2025144636A1

A device and method for detecting COVID-19 and other pathogens includes a sample compartment contained within an interior of the device and having multiple apertures for releasably receiving one or more test tubes containing a biological sample. A bottom portion of the test tube is contained within the interior of the device and a top portion of the test tube is exposed to atmosphere. The biological sample is lysed using the device; the lysed sample is mixed with one or more primers and then amplification (RT-LAMP) is performed using the device. A thermally conductive material on or in proximity to the sample compartment can facilitate precise heating of the compartment and sample. A thermally insulative material can be inside the interior of the housing. Multiple samples can be tested simultaneously. The results can be interpreted by a color change of the sample. The device is efficient, portable, reliable, and re-usable.

COMPOSITE PARTICLE FORMULATIONS AND APPLICATIONS THEREOF

Resumen de: US2025144040A1

Composite particle including the following: (1) a nanocrystal of an organic compound, and (2) a block copolymer associated with one or more surfaces of the nanocrystal of an organic compound. The organic compound, in some embodiments, is a pharmaceutical compound, a therapeutic compound, and/or a bioactive compound. The block copolymer may be a block copolymer with at least one hydrophilic poly(2-oxazoline) block. Pharmaceutical compositions may include these composite particles. The pharmaceutical compositions may include a dispersion that has an aqueous or aqueous-based continuous phase and a dispersed phase that includes the composite particles. The dispersion may be administered to sick patients, including those diagnosed with or exhibiting symptoms of COVID-19. For example, the dispersion may be aerosolized, and a patient may inhale the aerosol.

ACTIVATING ENDOGENOUS ANTIMICROBIALS TO TREAT SARS-COV-2 INFECTION

Resumen de: US2025144119A1

Provided herein are methods of treating COVID-19 in a subject in need thereof, comprising administering to the subject a 25-hydroxyvitamin D compound. Also provided herein are hard capsule dosage forms of 25-hydroxyvitamin. In aspects, the 25-hydroxyvitamin D is administered as a controlled release formulation, optionally an extended release oral formulation, such as Rayaldee® extended release calcifediol capsules. Methods of treating SARS-CoV-2 infection including reducing SARS-CoV-2 viral load are provided. Methods of treating SARS-CoV-2 infection including increasing an immune response are provided.

USE OF VE607 FOR THE TREATMENT OF SARS-COV-2 INFECTIONS AND RELATED DISEASES

Resumen de: US2025144087A1

The present application relates to the use of 3,3′-(1,3-phenylenebis(oxy))bis(1-(piperidin-1-yl)propan-2-ol (VE607) or a pharmaceutically acceptable salt thereof for the inhibition of SARS-CoV-2 and/or management of COVID-19.

HUMAN MONOCLONAL ANTIBODIES THAT BROADLY TARGET CORONAVIRUSES

Resumen de: US2025145690A1

Disclosed are monoclonal antibodies and antigen binding fragments that specifically bind a coronavirus spike protein, such as SARS-CoV-2. Also disclosed is the use of these antibodies for inhibiting a coronavirus infection. In addition, disclosed are methods for detecting a coronavirus in a biological sample, using the disclosed antibodies.

System and method for managing diagnostic testing and results

Nº publicación: GB2635230A 07/05/2025

Solicitante:

BHA GLOBAL LTD [MU]
BHA Global Ltd

Resumen de: GB2635230A

The present invention relates to a health and disease management system whereby a user performs a medical test on a device, whereafter the resulting test data is transmitted to an electronic database for verifying the test data and comparing the test data to benchmark data stored to derive one or more health and disease management recommendations. The device may be a self-test kit for a range of applications such as testing for COVID-19. The test data may include location data. The verification may authenticate the test results by comparing image data to an authenticity threshold value. Location data may be used to notify the user about a nearby health facility where treatment is available. A machine learning model may be trained to provide the disease management recommendations.